GILD Gilead Sciences Inc.

Gilead Sciences Announces Fourth Quarter 2016 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.47 per share of common stock for the fourth quarter of 2016. The dividend is payable on December 29, 2016, to stockholders of record at the close of business on December 15, 2016. Future dividends will be subject to Board approval.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

EN
01/11/2016

Underlying

GILDGilead Sciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gilead Sciences Inc.

Free Trial
GILD Gilead Sciences...

Gilead Sciences Inc: 1 director

A director at Gilead Sciences Inc sold 10,000 shares at 113.937USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

GILD GILEAD SCIENCES INC.
07/29/25 July 29, 2025 1 EN
GILD GILEAD SCIENCES INC.
12/18/24 December 18, 2024 1 EN
EUR 154.37
GILD Gilead Sciences...

Moody's Ratings assigns A3 rating to Gilead's notes; stable outlook

Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...

GILD GILEAD SCIENCES INC.
11/13/24 November 13, 2024 1 EN
EUR 214.40
GILD Gilead Sciences...

Gilead Sciences, Inc.: Update to credit analysis

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

GILD GILEAD SCIENCES INC.
10/28/24 October 28, 2024 1 EN
GILD Gilead Sciences...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 October 2024 in which we reassessed the appropriateness of the ratings in the cont...

GILD GILEAD SCIENCES INC.
10/21/24 October 21, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch